The National Cancer Institute: cancer drug discovery and development program
- PMID: 1462164
The National Cancer Institute: cancer drug discovery and development program
Abstract
The discovery and development of novel therapeutic products for the treatment of malignancy is vitally important to those physicians responsible for the management of cancer patients. A description of the ongoing efforts at the National Cancer Institute (NCI) is intended to provide insight into those complex processes necessary to accomplish this mission. An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future. The tremendous potential advantages and challenges associated with the use of a molecular approach to cancer drug design are discussed. Despite the differences of opinion that may exist regarding the optimal strategies for accomplishing the mission, there is no disagreement regarding the importance of the effort to find effective new therapies for cancer patients.
Similar articles
-
Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.Semin Oncol. 1997 Apr;24(2):219-40. Semin Oncol. 1997. PMID: 9129691 Review.
-
The preclinical new drug research program of the National Cancer Institute.Cancer Treat Rep. 1984 Jan;68(1):63-76. Cancer Treat Rep. 1984. PMID: 6692438
-
Developmental therapeutics program at the NCI: molecular target and drug discovery process.Leukemia. 2002 Apr;16(4):520-6. doi: 10.1038/sj.leu.2402464. Leukemia. 2002. PMID: 11960328 Review.
-
The role of the National Cancer Institute in drug development.Clin Adv Hematol Oncol. 2005 Apr;3(4):257-8. Clin Adv Hematol Oncol. 2005. PMID: 16166997 No abstract available.
-
Learning from exceptional drug responders.Nat Rev Drug Discov. 2014 Jun;13(6):401-2. doi: 10.1038/nrd4338. Nat Rev Drug Discov. 2014. PMID: 24875081 No abstract available.
Cited by
-
EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives.EXCLI J. 2014 May 26;13:573-85. eCollection 2014. EXCLI J. 2014. PMID: 26417284 Free PMC article.
-
Synthesis and Anticancer Evaluation of Some New 3-Benzyl-4,8-Dimethylbenzopyrone Derivatives.Open Med Chem J. 2017 Sep 21;11:81-91. doi: 10.2174/1874104501711010081. eCollection 2017. Open Med Chem J. 2017. PMID: 29151985 Free PMC article.
-
Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities.Molecules. 2016 Feb 26;21(3):271. doi: 10.3390/molecules21030271. Molecules. 2016. PMID: 26927048 Free PMC article.
-
Design, synthesis and biological evaluation of novel morpholinopyrimidine-5-carbonitrile derivatives as dual PI3K/mTOR inhibitors.RSC Med Chem. 2024 Feb 2;15(2):733-752. doi: 10.1039/d3md00693j. eCollection 2024 Feb 21. RSC Med Chem. 2024. PMID: 38389871 Free PMC article.
-
Improving Large Language Models' Summarization Accuracy by Adding Highlights to Discharge Notes: Comparative Evaluation.JMIR Med Inform. 2025 Jul 24;13:e66476. doi: 10.2196/66476. JMIR Med Inform. 2025. PMID: 40705416 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources